hydroxyalkane, a dihydroxyalkane, a polyethylene glycol having an average molecular weight of less than or equal to 1000 or mixtures thereof.

2. (Amended) A non-aqueous pharmaceutical composition consisting essentially of a taxane dissolved in a carrier system [composed] consisting essentially of a surfactant, a hydrophobic component comprising a triglyceride, diglyceride, monoglyceride, free fatty acid, fatty acid ester or mixtures thereof and hydrophilic phase comprising a hydroxyalkane, a dihydroxyalkane, polyethylene glycol having a molecular weight of at most 1000.

8. (Amended) A storage-stable, self-emulsifying preconcentrate of an anticancer drug in a non-aqueous microemulsion [composed] consisting essentially of:

10 to 80% w/w of a hydrophobic component of at least one triglyceride, diglyceride, monoglyceride, free fatty acid, fatty acid ester, fish oil, vegetable oil or mixtures thereof; 20 to 80% w/w of surfactant phase comprising at least one non-ionic surfactant,

0-35% w/w diethylene glycol monoethylether, and

0 to 40% w/w of at least one hydrophilic component selected from a hydroxyalkane, dihydroxyalkane, a polyethylene glycol having an average molecular weight of at most 1000, and mixtures thereof

wherein said preconcentrate, when mixed with an aqueous medium, gives an average particle size of at most 10 microns.

Claim 12, line 1, after "self-emulsifying," insert --non-aqueous,--

line 2, after "taxane" insert --in a composition--.

19. (Amended) A method of orally or parenterally administering an anticancer drug to a subject in need of same comprising administering a storage-stable, self-emulsifying, non-aqueous preconcentrate of a solubilized anticancer drug [composed] consisting essentially of:

10 to 80% w/w of a hydrophobic component of at least one triglyceride, diglyceride, monoglyceride, free fatty acid, fatty acid ester, fish oil, vegetable oil and mixtures thereof;

20 to 80% w/w of surfactant phase comprising at least one non-ionic surfactant, and

up to 40% w/w of at least one hydrophilic component selected from a hydroxy alkane, a dihydroxy alkane, a polyethylene glycol having an average molecular weight of at most 1000, and mixtures thereof

wherein said preconcentrate, when mixed with an aqueous medium, gives an average particle size of at most 10 microns.

20. (Amended) A method of [orally administering a self-emulsifying preconcentrate of] claim 12 [comprising] wherein the anticancer drug is a taxane solubilized in [a] the stable, self-emulsifying system which self-disperses in water, simulated intestinal, or simulated gastric fluid to yield a homogeneous phase with a particle size of below 10 microns.

Claim 21, line 2, after "self-emulsifying" insert --, non-aqueous--.